Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxychloroquine + peginterferon alfa-2a + ribavirin
- Development stage
- Unknown
- Lead developer
- Sheba Medical Center
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This investigational combination therapy consists of hydroxychloroquine added to the standard-of-care regimen of peginterferon alfa-2a and ribavirin. Developed by Sheba Medical Center, it was evaluated in a Phase I/II clinical trial for patients with chronic hepatitis C genotype 1 who had previously failed to respond to standard dual therapy. Hydroxychloroquine, a small molecule antimalarial, was included for its potential to inhibit autophagy and modulate the immune response, theoretically enhancing the virological response. Peginterferon alfa-2a (Pegasys) provides antiviral and immunomodulatory effects by binding to type I interferon receptors, while ribavirin (Copegus) acts as a nucleoside analog that interferes with viral RNA replication through multiple mechanisms, including inhibition of viral RNA polymerase and depletion of intracellular guanosine triphosphate pools.
- Brand names
- PegasysCopegus
- Other names
- HCQ + Peg-IFN + RBVHydroxychloroquine + Pegylated Interferon Alpha-2a + Ribavirin
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on hydroxychloroquine + peginterferon alfa-2a + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxychloroquine + peginterferon alfa-2a + ribavirin.